AFP and hepatocellular carcinoma: In advanced HCC patients with baseline AFP levels above 400 ng/mL who had progressed on prior sorafenib therapy, mOS (HR, 0.71; 95% CI, 0.53 – 0.95; p = 0.0199) and PFS (HR, 0.45; 95% CI, 0.34 – 0.60; p < 0.0001) were found to significantly favor ramucirumab monotherapy over placebo (16, 17).